Similar articles

• Reversal of cardiac hypertrophy and fibrosis by S21402, a dual inhibitor of neutral endopeptidase and angiotensin converting enzyme in SHRs.

  Farina NK, Johnston CI, Burrell LM. Farina NK, et al. J Hypertens. 2000 Jun;18(6):749-55. doi: 10.1097/00004872-200018060-00013. J Hypertens. 2000. PMID: 10872560
• Cardiac hypertrophy in experimental hypertension: interaction of the sodium ion, blood pressure and lisinopril.

  Fernandez D, Snedden W, Fernandez PG, Nath C, Vasdev S, Triggle CR, Lee C. Fernandez D, et al. Can J Cardiol. 1988 Jan-Feb;4(1):44-8. Can J Cardiol. 1988. PMID: 2834032
• The neutral endopeptidase inhibitor, SCH 34826, reduces left ventricular hypertrophy in spontaneously hypertensive rats.

  Monopoli A, Ongini E, Cigola E, Olivetti G. Monopoli A, et al. J Cardiovasc Pharmacol. 1992 Sep;20(3):496-504. doi: 10.1097/00005344-199209000-00023. J Cardiovasc Pharmacol. 1992. PMID: 1279298
• Cardiovascular hypertrophy in diabetic spontaneously hypertensive rats: optimizing blockade of the renin-angiotensin system.

  Lassila M, Davis BJ, Allen TJ, Burrell LM, Cooper ME, Cao Z. Lassila M, et al. Clin Sci (Lond). 2003 Apr;104(4):341-7. Clin Sci (Lond). 2003. PMID: 12653675
• SCH 34826: an overview of its profile as a neutral endopeptidase inhibitor and ANF potentiator.

  Sybertz EJ. Sybertz EJ. Clin Nephrol. 1991 Oct;36(4):187-91. Clin Nephrol. 1991. PMID: 1835684 Review.